HypercholesterolemiaMILOSNCT04579367
Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
An observational study of Hypercholesterolemia and Mixed Dyslipidemia, run by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company at 443 sites in 8 countries.
Trial summary
The primary objective is to describe in the real-world setting patient characteristics and outcomes of patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia using bempedoic acid and/or its fixed-dose combination with ezetimibe in managing plasma levels of… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypercholesterolemia, Mixed Dyslipidemia
- What is being tested?
- Bempedoic acid and/or its fixed-dose combination with ezetimibe
- How many people
- 5,000 participants
- Where
- 443 sitesin 8 countries
- Study dates
- 15 Jan 2021to 30 Oct 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will include participants with primary hypercholesterolemia or mixed dyslipidemia who are being treated with bempedoic acid and/or its fixed dose combination with ezetimibe.
Who may be able to join
- Written informed consent to participate
- At least 18 years of age
- Participants suffering from documented primary hypercholesterolemia or mixed dyslipidemia treated or intended to be treated with bempedoic acid and/or its fixed dose combination with ezetimibe at the discretion of the physician are appropriate for participation in the observation.
- No contraindications exist according to the SmPC of bempedoic acid and/or its fixed-dose combination with ezetimibe
- No concurrent participation in an interventional study (simultaneous participation in other non-interventional study is possible)
- Life expectancy > 1 year
Who cannot join
- As this is a non-interventional study, no explicit exclusion criteria are defined. The prescribing behavior will not be influenced. Only patients will be included where the decision has been made by the treating physician to treat the patients either with bempedoic acid and/or its fixed-dose combination with ezetimibe.
Trial locations and contacts
443 sites in 8 countries.
443 sites in 8 countries
Germany147 sites
Downtown Clinic Aachen
Aachen, 52062
Praxis Delonge
Aachen, 52078
Praxis Osterziel
Amberg, 92224
MVZ Helios Aue
Aue, 08280
Kardiologische Praxis Enders
Bad Elster, 08645
SLK-Klinikum am Plattenwald
Bad Friedrichshall, 74177
Herzcarre Praxis
Bad Homburg, 61348
Kardiologische Praxis
Bad Homburg, 61348
Zentrum für klinische Forschung
Bad Homburg, 61348
Universitätsklinikum Freiburg - Universitäts-Herzzentrum
Bad Krozingen, 79189
Praxis am Landratspark
Bad Segeberg, 23795
Hausärzte am Spritzenhaus
Baiersbronn, 72270
CIMS Studienzentrum Bamberg GmbH Drs. Kirschner/Haas/Ritzel
Bamberg, 96049
Kardiologische Praxis
Bechhofen, 66894
Praxis Rankestraße
Berlin, 10789
SKP Studienzentrum der kardiologischen Praxisgemeinschaft Rankestrasse GmbH
Berlin, 10789
Herzpraxis Berlin MVZ
Berlin, 12165
Charité - Universitätsmedizin Berlin
Berlin, 12203
Dres. Seeger & Partner
Berlin, 12627
Diabetespraxis Dr. Braun
Berlin, 13187
Lipidambulanz Charite
Berlin, 13353
Praxiszentrum Biedenkopf
Biedenkopf, 35216
Praxis Dr. A. Biedermann
Blankenhain, 99444
Kardiologische Gemeinschaftspraxis Bremerhaven
Bremerhaven, 27574
Kardiologie im Friedrichspalast Bruchsal
Bruchsal, 76646
Studiengesellschaft Könemann und Steinmann GbR
Bünde, 32257
MediClin Reha-Zentrum Spreewald
Burg, 03096
MVZ am Küchwald
Chemnitz, 09113
Kardiologische Praxis Stellmach
Chemnitz, 09126
MVZ Polymed
Chemnitz, 09130
Uniklinik Köln
Cologne, 50937
Zentrum für klinische Forschung
Cologne, 51069
IKAPP
Cologne, 51105
Praxis Dr. Menzel
Dessau, 06846
Klinikum Lippe GmbH
Detmold, 32756
Kardiologische Gemeinschaftspraxis
Dortmund, 44137
Cardiologicum Dresden/Pirna
Dresden, 01277
Hausärztliche Gemeinschaftspraxis mit diabetologischem Schwerpunkt
Dresden, 01279
Dres. Günther/Kolschmann
Dresden, 01307
Herzzentrum Dresden, Universitätsklinik an der Technischen Universität Dresden
Dresden, 01307
Universitätsklinikum Carl Gustav Carus
Dresden, 01307
DZDM Diabeteszentrum Duisburg Mitte
Duisburg, 47051
Nierenzentrum Düren
Düren, 52351
Universitätsklinikum Düsseldorf
Düsseldorf, 40225
Praxis Dilltal
Ehringshausen, 35630
Praxis Dipl. -Med. Petra Herrmann
Eisenach, 99817
Kardiologische Praxis
Elsterwerda, 04910
Gemeinschaftspraxis ISP Erlangen
Erlangen, 91052
Hausarztzentrum am Germaniaplatz
Essen, 45355
DIAKO Flensburg
Flensburg, 24939
Praxis für Nieren und Hochdruck-Krankheiten
Flensburg, 24941
MVZ Altstadt-Carree Fulda
Fulda, 36037
Klinikum Fulda
Fulda, 63043
Praxis Dr. Langel
Gera, 07551
Cardiocampus Gemeinschaftspraxis für Herz- und Kreislauferkrankungen
Gifhorn, 38518
Praxis für Gefäßmedizin
Görlitz, 02827
Universitätsmedizin Göttingen
Göttingen, 37075
Praxis Dr. Müller
Gräfenhainichen, 06773
Universitätsmedizin Greifswald
Greifswald, 17475
Evangelisches Krankenhaus Hagen-Haspe
Hagen, 58135
Praxis
Hainburg, 63512
Cardiologicum Hamburg - Praxis Wandsbek
Hamburg, 22041
Diabetes Zentrum Wandsbeck
Hamburg, 22041
MVZ Prof. Mathey, Prof. Schofer
Hamburg, 22527
Kardiologie am Tibarg
Hamburg, 22549
Kardiologie List
Hanover, 30177
Kardiologische Praxis
Hanover, 30559
Kardiologische Praxis
Haßloch, 67454
Kardiologische Schwerpunktpraxis
Heidelberg, 69115
Universitätsklinikum Heidelberg
Heidelberg, 69120
Praxis Heik/Wedig
Heiligenstadt, 37308
KARDIO-IN Kardiologische Gemeinschaftspraxis
Ingolstadt, 85049
Kardiologische Praxis
Kaiserslautern, 67655
SRH Klinikum Karlsbad-Langensteinbach
Karlsbad, 76307
B. Braun Ambulantes Herzzentrum Kassel
Kassel, 34121
Praxis Dr. Heiner Müller
Katzhütte, 98746
Nephrologie Kiel
Kiel, 24106
Gemeinschaftsklinikum Mittelrhein
Koblenz, 56068
Studienzentrum der Inneren Medizin I & II am Klinikum Konstanz
Konstanz, 78464
Kardiologie Dr. med. E. Persicke / Dr. med. O. Scheuermann
Kornwestheim, 70806
Kardiologische Praxis Kyritz
Kyritz, 16866
Universitätsklinikum Leipzig
Leipzig, 04103
Kardiologische Praxis Boudriot
Leipzig, 04129
MVZ Stoffwechselmedizin Leipzig
Leipzig, 04317
Praxis Dr. I.Simon-Wagner
Lichtenfels, 96215
St. Vincenz Krankenhaus
Limburg, 65549
Gemeinschaftspraxis Dr. Jens Biesenbaum und Dr. Uwe Gerbaulet
Löhne, 32584
Universität zu Lübeck
Lübeck, 23538
Cardio Centrum Ludwigsburg-Bietigheim
Ludwigsburg, 71634
Kardiologische Praxisklinik Ludwigshafen
Ludwigshafen, 67071
Institut für Präventive Medizin & Klinische Forschung GbR
Magdeburg, 39110
Cardiopraxis Mainz
Mainz, 55122
Katholisches Klinikum Mainz
Mainz, 55131
Universitätsklinikum Mainz
Mainz, 55131
ZE:RO Praxen
Mannheim, 68165
UMM Mannheim
Mannheim, 68167
Kardiologische Praxis
Markkleeberg, 04416
Praxis Ben-Chur
Meiningen, 98617
Praxis Haj-Yehia
Moers, 47441
Gemeinschaftspraxis Dr. Prohaska/Dr. Schulte
Mühldorf, 84453
Kardiologie Mühldorf am Inn
Mühldorf, 84453
Herzquartier Mülheim
Mülheim, 45468
Kardiologie Neuhausen-Nymphenburg
München, 80634
Dres. Wauer/Windstetter
München, 80799
Praxis Kiepenkerl
Münster, 48143
Zentrum für Kardiologie an der Raphaelsklinik Münster
Münster, 48143
Praxis für Innere Medizin Münster
Münster, 48149
Universitätsklinikum Münster
Münster, 48149
Internistische Praxisgemeinschaft
Neu-Isenburg, 63263
Kardiologische Praxis Northeim
Northeim, 37154
Hausarztpraxis
Oer-Erkenschwick, 45739
St. Vincenz-Krankenhaus GmbH
Paderborn, 33098
Kardiologische Praxis Papenburg - Site 6071
Papenburg, 26871
Kardiologische Praxis Papenburg - Site 6072
Papenburg, 26871
Gemeinschaftspraxis Dres. med. Karl-Heinz Göttl - Omar Adjan
Passau, 94032
Hausärztlich-Kardiologisches MVZ "Am Felsenkeller" GmbH
Pirna, 01796
Kinikum Ernst von Bergmann
Potsdam, 14467
VieSante Herzmedizin Potsdam
Potsdam, 14469
Kardiologische Gemeinschaftspraxis
Potsdam, 14471
Allgemeinmedizinisch Internistische Praxis Dr. H. Borgmann
Radebeul, 01445
Internistisch hausärtzliche Gemeinschaftspraxis Dr. Hildebrandt & Dr. Mutscher
Radebeul, 01445
Gemeinschaftspraxis Herz Riesa
Riesa, 01587
Universitätsmedizin Rostock
Rostock, 18057
Facharztpraxis für Kardiologie und Innere Medizin
Schwäbisch Hall, 74523
MVZ Schwerin West GmbH
Schwerin, 19057
Nierenzentrum Altmark
Seehausen, 39615
Zentrum für Prävention und Rehabilitation
Siegen, 57072
Klinik Singen
Singen, 78224
MEDINOS Klinik Sonneberg
Sonneberg, 96515
Kardiologische Praxis im Steiner Thor
Straubing, 94315
Praxis Dr Knöbel u. Partner
Straubing, 94315
Praxis Dr. Michael Rother
Strausberg, 15344
Diabetologische Schwerpunktpraxis
Trier, 54292
Krankenhaus der Barmherzigen Brüder Trier
Trier, 54292
Studienzentrum der Herzklinik Ulm GbR
Ulm, 89077
Praxis Dr. Hansen
Unterwellenborn, 07333
Praxis Dr. Dengler/Hohenstatt
Ursensollen, 92289
Herzzentrum Saar
Völklingen, 66333
GRN Weinheim
Weinheim, 69469
Kardiologische Praxis Al-Zoebi
Wermsdorf, 04779
Internistische Gemeinschaftspraxis Dr. med. Schreckenberg, Dr. med. Vorderstraße
Weyhe, 28844
Forschungszentrum-Ruhr / KliFoCenter GmbH
Witten, 58455
Kardiologische Praxis Tamm/Hoh
Wittenberg, 06886
Kardiologische Fachpraxis
Wolmirstedt, 39326
Zentrum für Nieren- und Hochdrucklerkrankungen Hofaue
Wuppertal, 42103
Universitätsklinikum Würzburg
Würzburg, 97080
Gemeinschaftspraxis am Angerbrunnen
Zwiesel, 94227
Italy104 sites
Ospedale Generale Regionale "F. Miulli"
Acquaviva delle Fonti, 70021
P.O. Agrigento Ospedale San Giovanni di Dio
Agrigento, 92100
IRCCS-INRCA Ancona
Ancona, 60127
Ospedale di Anzio
Anzio, 00042
Ospedale dei Castelli
Ariccia, 00072
Ospedale "C. e G. Mazzoni"
Ascoli Piceno, 63100
A.O. San Giuseppe Moscati
Avellino, 83100
Ospedale SS Nicola e Filippo
Avezzano, 67051
Ospedale S. Paolo
Bari, 70123
A.O.U. Consorziale - Policlinico Bari
Bari, 70124
Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari - Site 08016
Bari, 70124
Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari - Site 08017
Bari, 70124
AUSL Bologna Ospedale di Bentivoglio
Bentivoglio, 40010
ASST Papa Giovanni XXIII
Bergamo, 24127
Ospedale Maggiore Carlo Alberto Pizzardi
Bologna, 40133
Policlinico Sant'Orsola Bologna-Malpighi
Bologna, 40138
Ospedale di Bolzano - Site 08070
Bolzano, 39100
Ospedale di Bolzano - Site 08112
Bolzano, 39100
Spedali Civili di Brescia
Brescia, 25123
Ospedale Santo Spirito Casale Monferrato
Casale Monferrato, 15033
A.O. S. Anna e S. Sebastiano
Caserta, 81100
ULLS 2 MARCA TREVIGIANA Ospedale di Castelfranco Veneto
Castelfranco Veneto, 31033
AOU Policlinico Vittorio Emanuele Presidio Ospedaliero Gaspare Rodolico
Catania, 95124
Azienda Ospedaliera Cannizzaro
Catania, 95126
L'Azienda Ospedaliero-Universitaria "Renato Dulbecco" di Catanzaro
Catanzaro, 88100
Ospedale Civile Santa Maria Incoronata dell'Olmo
Cava de' Tirreni, 84013
Policlinico SS. Annunziata
Chieti, 66100
ASL TO4 Presidio Riunito di Ciriè-Lanzo
Cirié, 10073
Azienda Ospedaliero-Universitaria di Ferrara "Arcispedale Sant'Anna"
Cona, 44124
Ospedale San Salvatore
Coppito, 67100
Ospedale Santa Maria Nuova
Florence, 50122
AOU Careggi - Site 08067
Florence, 50134
AOU Careggi - Site 08081
Florence, 50134
AOU Careggi - Site 08090
Florence, 50134
Azienda Ospedaliera Universitaria "Ospedali Riuniti" di Foggia
Foggia, 71122
Ospedale Policlinico San Martino
Genova, 16132
Presidio Ospedaliero S.O. Padre Antero Micone
Genova, 16153
Ospedale della Misericordia
Grosseto, 58100
Ospedale Sant'Andrea
La Spezia, 19121
ASP Catanzaro Presidio Ospedaliero "Giovanni Paolo II"
Lamezia Terme, 88046
Ospedale Vito Fazzi
Lecce, 73100
Ospedale Mater Salutis
Legnago, 37045
Presidio Ospedaliero "Madonna delle Grazie"
Matera, 75100
Presidio ospedaliero San Giovanni di Dio
Melfi, 85025
A.O.U. Policlinico "G. Martino"
Messina, 98124
ULSS 3 SERENISSIMA Ospedale dell'Angelo
Mestre, 30174
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Site 08039
Milan, 20122
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Site 08097
Milan, 20122
Centro Cardiologico Monzino
Milan, 20138
Ospedale San Luca - Gruppo Istituto Auxologico Italiano
Milan, 20149
ASST Grande Ospedale Metropolitano Niguarda
Milan, 20162
Ospedale Niguarda
Milan, 20162
ULSS 3 Serenissima Presidio Ospedaliero di Mirano
Mirano, 30035
AOU Modena Policlinico Modena
Modena, 41125
A.O.R.N. Antonio Cardarelli
Naples, 80131
A.O.R.N. MONALDI OSPEDALE DEI COLLI Ospedale Monaldi
Naples, 80131
A.O.U. Federico Ii
Naples, 80131
Azienda Ospedaliera Specialistica dei Colli Ospedale Monaldi
Naples, 80131
Policlinico Università Federico II - Napoli
Naples, 80131
Ospedale Umberto I
Nocera Inferiore, 84014
AOU Maggiore della Carità di Novara
Novara, 28100
Ospedale San Giacomo
Novi Ligure, 15067
Azienda ospedaliera-Università di Padova
Padova, 35128
A.O.U. Policlinico "P. Giaccone"
Palermo, 90127
Casa di Cura Triolo Zancla Hospital
Palermo, 90133
ICS Maugeri
Pavia, 27100
USL Umbria I
Perugia, 06126
Azienda Ospedaliera S. Maria della Misericordia di Perugia
Perugia, 06129
Ospedale Guglielmo da Saliceto
Piacenza, 29121
Fondazione Monasterio
Pisa, 56124
P. O. Portogruaro
Portogruaro, 30026
Azienda Ospedaliera Regionale San Carlo di Potenza
Potenza, 85100
Nuovo Ospedale Santo Stefano
Prato, 59100
Azienda Sanitaria Provinciale di Ragusa Ospedale Giovanni Paolo II
Ragusa, 97100
Ospedale Santa Maria delle Croci
Ravenna, 48121
ASST Rhodense - Ospedale di Circolo di Rho
Rho, 20017
Ospedale San Camillo De Lellis
Rieti, 02100
Ospedale Infermi AUSL Romagna
Rimini, 47923
Ospedale degli Infermi di Rivoli
Rivoli, 10098
Policlinico Tor Vergata
Roma, 00133
Ospedale Sandro Pertini
Roma, 00157
Policlinico Umberto I
Roma, 00161
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Site 08046
Roma, 00168
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Site 08121
Roma, 00168
Policlinico Casilino
Roma, 00169
AOU S. Andrea
Roma, 00189
A.O. San Giovanni di Dio e Ruggi D'Aragona
Salerno, 84131
ASST Valle Olona P.O. Saronno
Saronno, 21047
Ospedale S. Bartolomeo
Sarzana, 19038
AOU Sassari Ospedale SS. Annunziata
Sassari, 07100
IRCCS Multimedica
Sesto San Giovanni, 20099
A.O.U. Senese Ospedale Santa Maria alle Scotte
Siena, 53100
AOU Senese- Policlinico Le Scotte
Siena, 53100
Casa di cura Villa Verde
Taranto, 74121
Azienda Ospedaliera Santa Maria
Terni, 05100
Ospedale Mauriziano Presidio Umberto I
Torino, 10128
AOU Ospedali Riuniti di Ancona
Torrette, 60126
Ospedale Santa Chiara
Trento, 38122
ULLS 2 MARCA TREVIGIANA Ospedale Ca' Foncello
Treviso, 31100
Ospedale di Cattinara
Trieste, 34149
Ospedale Santa Maria della Misericordia
Udine, 33100
Ospedale Santa Maria della Misericordia
Urbino, 61029
ASST Settelaghi Ospedale di Circolo e Fondazione Macchi
Varese, 21100
Ospedale Castelli Verbania
Verbania, 28922
Spain66 sites
Hospital General de Albacete
Albacete, 02006
Hospital Universitario Fundación Alcorcón
Alcorcón, 28922
Hospital Virgen de los Lirios
Alcoy, 03804
Hospital General Universitario Dr. Balmis
Alicante, 03010
Hospital Universitario Torrecárdenas
Almería, 04009
Hospital Universitario Central de Asturias
Asturias, 33011
Clínica Mapfre Salud Gijón
Asturias, 33202
Hospital Universitario San Agustin
Asturias, 33410
Hospital Universitario Nuestra Señora del Perpetuo Socorro
Badajoz, 06010
Hospital Universitario de Cruces
Barakaldo, 48903
Hospital de Bellvitge
Barcelona, 08902
Hospital Universitario de Basurto
Bilbao, 48013
Hospital Universitario de Burgos
Burgos, 09003
Hospital Universitario San Pedro de Alcántara
Cáceres, 10003
Hospital Universitario Puerta del Mar
Cadiz, 11009
Hospital General Universitario de Castellón
Castellon, 12004
Hospital Universitario Reina Sofía
Córdoba, 14004
Hospital del Henares
Coslada, Madrid, 28822
Hospital de Denia
Denia, 03700
Hospital UNiversitario de Donostia
Donostia / San Sebastian, 20014
Hospital de Fuenlabrada
Fuenlabrada Madrid, 28942
Hospital Universitario de Cabueñes
Gijón, 33394
Hospital Universitario Virgen de las Nieves
Granada, 18013
Hospital Universitario San Cecilio
Granada, 18016
Hospital Universitario Juan Ramón Jiménez
Huelva, 21110
Hospital Universitario Médico-Quirúrgico de Jaén
Jaén, 23007
Hospital Jerez de la Frontera
Jerez de La Frontera, Cádiz, 11407
Hospital Universitario de Gran Canaria Dr. Negrín
Las Palmas de Gran Canaria, 35010
Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria
Las Palmas de Gran Canaria, 35016
Hospital Universitario de León
León, 24008
Hospital San Pedro
Logroño, 26006
Hospital UNiversitario la Princesa
Madrid, 28006
Hospital Universitario Gregorio Marañón
Madrid, 28007
Hospital Ruber Internacional
Madrid, 28034
Hospital Universitario Ramón y Cajal
Madrid, 28034
Hospital Clínico San Carlos
Madrid, 28040
Hospital Clínico Universitario San Carlos
Madrid, 28040
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040
Hospital Universitario 12 de Octubre
Madrid, 28041
Hospital Universitario La Paz
Madrid, 28046
Hospital HM Montepríncipe
Madrid, 28660
Hospital Universitario de Torrejón
Madrid, 28850
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda Madrid, 28222
Hospital Universitario Puerta de Hierro Majadahonda
Majdahonda Madrid, 28222
Consulta de Cardiología Dr. Javier Mora Robles
Málaga, 29002
Hospital Regional Universitario de Málaga
Málaga, 29010
Hospital Universitario Virgen de la Victoria
Málaga, 29010
Hospital Costa del Sol
Marbella Málaga, 29603
Hospital de Mendaro
Mendaro, 20850
Hospital General Universitario Reina Sofía
Murcia, 30003
Hospital Clínico Universitario Virgen Arrixaca
Murcia, 30120
Hospital Universitario Son LLatzer
Palma de Mallorca, 07193
Hospital Universitario de Navarra
Pamplona, 31008
Hospital de Sagunto
Port de Sagunt, 46520
Hospital Universitario Marqués de Valdecilla
Santander, 39008
Hospital de Valme
Seville, 41014
Hospital Universitario Vírgen del Rocío
Seville, 411013
Hospital General Universitario de Toledo
Toledo, 45007
Hospital Clínico Universitario de Valencia
Valencia, 46010
Hospital Arnau de Vilanova
Valencia, 46015
Vithas Valencia 9 de Octubre
Valencia, 46015
Consorcio Hospital General Universitario de Valencia
Valencia, 46016
Hospital Universitari i Politècnic La Fe
Valencia, 46026
Hospital Universitario Rio Hortega
Valladolid, 47130
Hospital de La Plana
Villarreal, Castellón, 12540
Hospital Clinico Universitaro Lozano Blesa
Zaragoza, 50009
Belgium36 sites
ASZ
Aalst, 9300
Clinique Saint-Luc Bouge Namur
Bouge, B-5005
Epicura Hornu
Boussu, B-7301
A.Z. KLINA Brasschaat
Brasschaat, B-2930
Clinique Saint-Jean Bruxelles
Brussels, B-1000
CHU Brugman
Brussels, B-1020
CUB-Hôpital Erasme
Brussels, B-1070
UZ Brussel
Brussels, B-1090
Clinique de l'Europe Saint Elisabeth
Brussels, B-1180
UCL Saint-Luc Woluwé Bruxelles
Brussels, B-1200
Private Practice
Ciney, B-5590
Az Sint Blazius
Dendermonde, 9200
UZ Antwerpen
Edegem, B-2650
Z.O.L - Campus St. Jan
Genk, B-3600
AZ St-Lucas & Volkskliniek
Ghent, B-9000
UZ Gent
Ghent, B-9000
GHDC Charleroi - Site Hôpital Saint-Joseph
Gilly, B-6060
Private Practice
Gribomont, B-6887
Pôle hospitalier Jolimont
Haine-Saint-Paul, B-7100
BVBA Med Kab
Halen, B-3545
Jessa Ziekenhuis
Hasselt, B-3500
CHR Huy
Huy, B-4500
JAN YPERMAN Ziekenhuis
Ieper, B-9800
AZ Groeninge Kortrijk
Kortrijk, B-8500
CHU Tivoli
La Louvière, B-7100
UZ Leuven
Leuven, B-3000
CHR Citadelle de Liège
Liège, B-4000
CHU Liège
Liège, B-4000
CHU Charleroi Hopital civil Marie-Curie
Lodelinsart, B-6042
CHU Mons Ambroise Paré
Mons, B-7000
AZ Sint Jan
Ostend, B-8400
AZ Delta
Roeselare, B-8800
AZ Glorieux
Ronse, B-9600
Sint Trudo
Sint-Truiden, B-3800
Sint-Andriesziekenhuis Tielt
Tielt, B-8700
CHU UCL Mont-Godinne
Yvoir, B-5530
United Kingdom32 sites
Royal United Hospitals Bath NHS Foundation Trust
Bath, BA1 3NG
South Eastern Ulster Hospital
Belfast, BT16 1RH
University Hospital of Wales
Cardiff, CF64 2XX
Rowden Surgery
Chippenham, SN15 2SB
Craigavon Area Hospital
Craigavon, BT63 5QQ
Darlington Memorial Hospital
Darlington, DL3 6HX
University Hospital North Durham
Durham, DH1 5TW
Oaks Healthcare
Hampshire, PO8 8DL
West Morland General Hospital
Kendal, LA9 7RG
North Blaby PCN
Leicester, LE19 4LY
Barts Health NHS Trust/ QMUL
London, EC1M 6BQ
Freuchen Medical Centre
London, NW10 4ST
Royal Free Hospital Lipid Clinic
London, NW3 2QG
Hammersmith Hospital
London, W12 0HS
Imperial College London
London, W6 8RP
Manchester Royal Infirmary
Manchester, M13 9WL
Manchester University NHS Foundation Trust
Manchester, M13 9WL
Manchester University NHS Foundation Trust
Manchester, M23 9LT
Wythenshawe Hospital
Manchester, M23 9LT
STRIVE, The James Cook University Hospital
Middlesbrough, TS4 3BW
North Tees Hospital
Northumbria, TS19 8PE
City Hospital
Nottingham, NG5 1PB
Queen Alexandra Hospital
Portsmouth, PO6 3LY
Whiston Hospital
Prescot, L35 5DR
North Manchester General Hospital
Salford, M6 8HD
Queen's Hospital Lipid Clinic
Staffordshire, DE13 0RB
Princess Royal Hospital
Telford, TF1 6TF
Torbay and South Devon NHS Foundation Trust
Torquay, TQ2 7AA
Trowbridge Health Centre
Trowbridge, BA14 8LW
North Wales Cardiac Centre
Wales, LL57 2PW
Wansford and Kings Cliffe Practice
Wansford, PE8 6PL
Bridgewater Surgeries
Watford, WD18 7QR
Netherlands21 sites
ZGT
Almelo, 7609 PP
Meander Mc
Amersfoort, 3813 TZ
AUMC
Amsterdam, 1105 AZ
Mc Leeuwarden
Amsterdam, 8934 AD
Rijnstate
Arnhem, 6815 AD
AMPHIA
Breda, 4818 CK
Albert Schweitzer
Dordrecht, 3318 AT
ZGV
Ede, 6716 RP
Maxima Medisch Centrum
Eindhoven, 5631 BM
GHZ
Gouda, 2803 HH
Spaarne Gasthuis
Haarlem, 2035 RC
Saxenburgh Medisch Centrum
Hardenberg, 7772 SE
Tergooi Mc
Hilversum, 1212 VG
Treant Bethesda Hoogeveen
Hoogeveen, 7900 RA
Dijklander
Hoorn, 1624 NP
ALRIJNE
Leiderdorp, 2353 GA
MUMC+
Maastricht, 6229 HX
Erasmus Mc
Rotterdam, 3015 GD
Franciscus Gasthuis
Rotterdam, 3045 PM
MAASSTAD
Rotterdam, 3079 DZ
Isala Zwolle
Zwolle, 8025 AB
Austria20 sites
Dr. Armin Öhlinger Kardiologe & innere Medizin
Dornbirn, 6850
Landeskrankenhaus Feldkirch
Feldkirch, 6807
LKH-Univ. Klinikum Graz
Graz, 8036
Medizinische Universität Graz
Graz, 8036
Internist Dr. med. univ. Stefan Moser
Hörsching, 4063
Medizinische Universität Innsbruck
Innsbruck, 6020
KABEG Klinikum Klagenfurt am Wörthersee
Klagenfurt, 9020
Konventhospital der Barmherzigen Brüder Linz
Linz, 4020
Ordination Dr. Johannes Föchterle
Linz, 4040
Ordination Frau Prof. Dr. Yvonne Winhofer-Stöckl
Mattersburg, 7210
Kompetenz-Zentrum Diabetes
Salzburg, 5026
Ordination Universitätsdozent Dr. Alexander Kober
Sankt Aegyd am Neuwalde, 3193
Ordination Dr. med. univ. Evelyn Fließer-Görzer
Sankt Stefan ob Stainz, 8511
Ordination Dr. Thomas Maca
Vienna, 1010
Klinik Hietzing, Wiener Gesundheitsverbund
Vienna, 1030
Zentrum für Klinische Studien Dr. Hanusch GmbH
Vienna, 1060
Allgemeines Krankenhaus der Stadt Wien
Vienna, 1090
Univ.-Prof. Dr. Thomas Stulnig
Vienna, 1130
Herz Zentrum Währing
Vienna, 1180
Karl Landsteiner Institut für kardiovaskuläre und intensivmedizinische Forschung
Vienna, 1210
Switzerland17 sites
Diabetologie & Endokrinologie Baden
Baden, 5400
University Hospital Basel
Basel, 4031
Inselspital, Universitätsspital Bern
Bern, 3010
Praxis Dr. med Urs Beat Gröflin
Binningen, 4102
Hochgebirgsklinik Davos
Davos, 7265
Spital Lachen AG
Lachen, 8853
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, 1011
University of Lausanne
Lausanne, 1011
Kantonsspital Baselland
Liestal, 4410
EOC Ente Ospedaliero Cantonale
Lugano, 6900
MIP Associazione Medico in Pratica c/o Studio Medico Cardiologico Acquistapace
Lugano, 6900
Praxis Prof. Dr. med. Gottfried Rudofsky
Olten, 4600
HÔPITAL RIVIERA-CHABLAIS, VAUD-VALAIS, Centre hospitalier de Rennaz
Rennaz, 1847
Kantonsspital St.Gallen
Sankt Gallen, CH-9007
Spital Thun
Thun, 3600
Prof. Dr. med. Stephane Bosquet
Yverdon-les-Bains, 1400
Universitätsspital Zürich
Zurich, 8091
About this study
Official title: Non-interventional Study on the Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (MILOS)
The primary objective is to describe in the real-world setting patient characteristics and outcomes of patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia using bempedoic acid and/or its fixed-dose combination with ezetimibe in managing plasma levels of low-density lipoprotein cholesterol (LDL-C).
Secondary objectives are to document and evaluate as applicable:
- Assessment of the cardiovascular risk of patients treated with bempedoic acid and/or its fixed-dose combination with ezetimibe using different risk scores (e.g. Systematic Coronary Risk Estimation (SCORE) system, SMART score for Very High Risk patients and Framingham risk score for High Risk patients. The scores will be re-calculated during the analysis and used as an analytical tool only).
- Changes in low-density lipoprotein cholesterol (LDL-C) levels prior to treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe compared to 1 year follow-up and subsequent data collection points, if applicable.
- Characterize plasma levels of other potentially ASCVD-modifying cholesterol fragments, namely, LDL-C, total cholesterol (TC), apolipoprotein B (apoB), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, triglycerides (TGs) and lipoprotein A (Lp[a]) compared to 1 year follow-up and subsequent data collection points, if applicable.
- Changes in the levels of inflammatory marker hsCRP compared to 1 year follow-up and subsequent data collection points, if applicable.
- Adverse Drug Reactions associated to bempedoic acid and/or its fixed-dose combination with ezetimibe.
- Changes in uric acid levels compared to 1 year follow-up and subsequent data collection points, if applicable.
- Relevant CV events:
- Myocardial infarction
- Unstable angina
- Coronary artery bypass graft surgery (CABG)
- Percutaneous transluminal coronary angioplasty (PTCA)
- Stroke
- Transient ischemic attack (TIA)
- Acute peripheral arterial occlusion
- All-cause death
- Cardiovascular (CV)-death
- Adverse effects associated with lipid-modifying treatment (LMT)
- Laboratory abnormalities
- Muscle-associated symptoms
- New onset and/or worsening diabetes
- Changes in the patients´ glycemic status over time
- Site characteristics (sites and practitioners) caring for patients treated with bempedoic acid and/or its fixed-dose combination with ezetimibe.
- Use of LMTs prior or concomitantly to receiving bempedoic acid and/or its fixed-dose combination with ezetimibe (therapies including combination treatments).
- Bempedoic acid and/or its fixed-dose combination with ezetimibe treatment parameters such as treatment duration by therapy, dosage, prescription intervals, permanent discontinuations, switches and reasons for these, (concomitant medication, additional therapy/interventions).
- Healthcare resource use especially consultation visits with specialist, nurse time and hospitalizations as well as patient-reported outcome using EQ-5D-5L and PAM-13.
Read the detailed description
This non-interventional study will be conducted to characterize the risks and benefits of bempedoic acid and/or its fixed-dose combination with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia or mixed dyslipidaemia and to gain insight into the effectiveness (managing plasma levels of low-density lipoprotein cholesterol) as well as safety (clinical events associated with the treatment modalities). Real world evidence will be collected in 5000 participants, treated by specialized as well as non-specialized physicians in hospitals and office based centers.
- Conditions
- Hypercholesterolemia, Mixed Dyslipidemia
- Being tested
- Bempedoic acid and/or its fixed-dose combination with ezetimibe
- Keywords
- Hypercholesterolemia, Mixed dyslipidemia, Bempedoic acid and/or its fixed-dose combination with ezetimibe
- Medical subject headings
- Hypercholesterolemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bempedoic acid and/or its fixed-dose combination with ezetimibeDrug
This is a non-interventional study. No study medication will be provided to the patients. Medication will be prescribed by the treating physician in line with the clinical practice.
| Study group | Role | What they receive |
|---|---|---|
| Bempedoic acid and/or fixed-dose combination with ezetimibe | Participants with primary hypercholesterolemia or mixed dyslipidemia who received bempedoic acid and/or its fixed-dose combination with ezetimibe. Receives: Drug: Bempedoic acid and/or its fixed-dose combination with ezetimibe |
What is being measured
The primary outcome is the main question the study is designed to answer.
Summary of patient characteristics in patients with primary hypercholesterolemia or mixed dyslipidemia following treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe
Measured: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)
Secondary outcomes (4)
Overview of the cardiovascular risk of patients with primary hypercholesterolemia or mixed dyslipidemia following treatment with bempedoic acid/ and/or its fixed-dose combination with ezetimibe
Cardiovascular risk scores will be assessed using the Systematic Coronary Risk Estimation (SCORE) system, Second manifestations of arterial disease (SMART) and Framingham risk scores. The SMART risk score will estimate 10-year risk for very high-risk participants based on clinical patient characteristics. The gender-specific Framingham risk score will be used to estimate 10-year cardiovascular risk for high-risk participants.
Measured: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)
Summary of changes in plasma low-density lipoprotein cholesterol levels following treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe in patients with primary hypercholesterolemia or mixed dyslipidemia
Measured: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)
Summary in changes in plasma levels of atherosclerotic cardiovascular disease-modifying cholesterol fragments following treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe
Plasma levels of total cholesterol (TC), apolipoprotein B (apoB), high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs) and lipoprotein a (Lp[a]) will be assessed.
Measured: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)
Summary of changes in plasma inflammatory marker hsCRP levels following treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe in patients with primary hypercholesterolemia or mixed dyslipidemia
Inflammatory status was assessed using high-sensitive C-reactive protein.
Measured: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2020
- Study start15 Jan 2021
- Primary completion30 Oct 2026 (estimated)
- Study completion30 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypercholesterolemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Global Clinical Leader, Study director, Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04579367
- Sponsor's protocol ID
- DSE-BMP-01-20-EU
- Acronym
- MILOS
- Status last verified
- Sep 2026
- First submitted
- 1 Oct 2020
- Last updated
- 30 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-interventional Study on the Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (MILOS)
- ClinicalTrials.gov ID
- NCT04579367
- Acronym / sponsor ID
- MILOS / DSE-BMP-01-20-EU
- Conditions
- Hypercholesterolemia, Mixed Dyslipidemia
- Keywords
- Hypercholesterolemia, Mixed dyslipidemia, Bempedoic acid and/or its fixed-dose combination with ezetimibe
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyIndustry (pharma, biotech, devices)
- Study start
- 15 Jan 2021 (actual)
- Primary completion
- 30 Oct 2026 (estimated)
- Study completion
- 30 Oct 2026 (estimated)
- First posted
- 8 Oct 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective is to describe in the real-world setting patient characteristics and outcomes of patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia using bempedoic acid and/or its fixed-dose combination with ezetimibe in managing plasma levels of low-density lipoprotein cholesterol (LDL-C).
Secondary objectives are to document and evaluate as applicable:
- Assessment of the cardiovascular risk of patients treated with bempedoic acid and/or its fixed-dose combination with ezetimibe using different risk scores (e.g. Systematic Coronary Risk Estimation (SCORE) system, SMART score for Very High Risk patients and Framingham risk score for High Risk patients. The scores will be re-calculated during the analysis and used as an analytical tool only).
- Changes in low-density lipoprotein cholesterol (LDL-C) levels prior to treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe compared to 1 year follow-up and subsequent data collection points, if applicable.
- Characterize plasma levels of other potentially ASCVD-modifying cholesterol fragments, namely, LDL-C, total cholesterol (TC), apolipoprotein B (apoB), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, triglycerides (TGs) and lipoprotein A (Lp[a]) compared to 1 year follow-up and subsequent data collection points, if applicable.
- Changes in the levels of inflammatory marker hsCRP compared to 1 year follow-up and subsequent data collection points, if applicable.
- Adverse Drug Reactions associated to bempedoic acid and/or its fixed-dose combination with ezetimibe.
- Changes in uric acid levels compared to 1 year follow-up and subsequent data collection points, if applicable.
- Relevant CV events:
- Myocardial infarction
- Unstable angina
- Coronary artery bypass graft surgery (CABG)
- Percutaneous transluminal coronary angioplasty (PTCA)
- Stroke
- Transient ischemic attack (TIA)
- Acute peripheral arterial occlusion
- All-cause death
- Cardiovascular (CV)-death
- Adverse effects associated with lipid-modifying treatment (LMT)
- Laboratory abnormalities
- Muscle-associated symptoms
- New onset and/or worsening diabetes
- Changes in the patients´ glycemic status over time
- Site characteristics (sites and practitioners) caring for patients treated with bempedoic acid and/or its fixed-dose combination with ezetimibe.
- Use of LMTs prior or concomitantly to receiving bempedoic acid and/or its fixed-dose combination with ezetimibe (therapies including combination treatments).
- Bempedoic acid and/or its fixed-dose combination with ezetimibe treatment parameters such as treatment duration by therapy, dosage, prescription intervals, permanent discontinuations, switches and reasons for these, (concomitant medication, additional therapy/interventions).
- Healthcare resource use especially consultation visits with specialist, nurse time and hospitalizations as well as patient-reported outcome using EQ-5D-5L and PAM-13.
Detailed description
This non-interventional study will be conducted to characterize the risks and benefits of bempedoic acid and/or its fixed-dose combination with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia or mixed dyslipidaemia and to gain insight into the effectiveness (managing plasma levels of low-density lipoprotein cholesterol) as well as safety (clinical events associated with the treatment modalities). Real world evidence will be collected in 5000 participants, treated by specialized as well as non-specialized physicians in hospitals and office based centers.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Bempedoic acid and/or fixed-dose combination with ezetimibe | – | Drug: Bempedoic acid and/or its fixed-dose combination with ezetimibeParticipants with primary hypercholesterolemia or mixed dyslipidemia who received bempedoic acid and/or its fixed-dose combination with ezetimibe. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will include participants with primary hypercholesterolemia or mixed dyslipidemia who are being treated with bempedoic acid and/or its fixed dose combination with ezetimibe.
Key inclusion criteria (6 listed)
- Written informed consent to participate
- At least 18 years of age
- Participants suffering from documented primary hypercholesterolemia or mixed dyslipidemia treated or intended to be treated with bempedoic acid and/or its fixed dose combination with ezetimibe at the discretion of the physician are appropriate for participation in the observation.
- No contraindications exist according to the SmPC of bempedoic acid and/or its fixed-dose combination with ezetimibe
- No concurrent participation in an interventional study (simultaneous participation in other non-interventional study is possible)
Key exclusion criteria (1 listed)
- As this is a non-interventional study, no explicit exclusion criteria are defined. The prescribing behavior will not be influenced. Only patients will be included where the decision has been made by the treating physician to treat the patients either with bempedoic acid and/or its fixed-dose combination with ezetimibe.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bempedoic acid and/or its fixed-dose combination with ezetimibeThis is a non-interventional study. No study medication will be provided to the patients. Medication will be prescribed by the treating physician in line with the clinical practice. | Drug | Bempedoic acid and/or fixed-dose combination with ezetimibe |
Primary outcome
Summary of patient characteristics in patients with primary hypercholesterolemia or mixed dyslipidemia following treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe
Time frame: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)
4 secondary outcomes
Overview of the cardiovascular risk of patients with primary hypercholesterolemia or mixed dyslipidemia following treatment with bempedoic acid/ and/or its fixed-dose combination with ezetimibe
Time frame: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)
Summary of changes in plasma low-density lipoprotein cholesterol levels following treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe in patients with primary hypercholesterolemia or mixed dyslipidemia
Time frame: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)
Summary in changes in plasma levels of atherosclerotic cardiovascular disease-modifying cholesterol fragments following treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe
Time frame: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)
Summary of changes in plasma inflammatory marker hsCRP levels following treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe in patients with primary hypercholesterolemia or mixed dyslipidemia
Time frame: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Related trials for Hypercholesterolemia
RecruitingObservational study
Causes and Natural History of Dyslipidemias
Hypercholesterolemia, Atherosclerosis
Active, not recruitingObservational study
Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia
Heterozygous Familial Hypercholesterolemia
RecruitingPhase 4
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
RecruitingObservational study
A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe
Hypercholesterolemia, Dyslipidemias
RecruitingPhase 3
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Global Clinical Leader study director
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
443 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypercholesterolemia and Mixed Dyslipidemia, run by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company at 443 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 443 sites in Germany, Italy, Spain, Belgium, United Kingdom and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Summary of patient characteristics in patients with primary hypercholesterolemia or mixed dyslipidemia following treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe (time frame: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026; AzTrials last refreshed its copy on 31 Oct 2026.